Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

VANGUARD

Financiado

Cerrado

New Generation Cell Therapy Bioartificial Pancreas to Cure Type 1 Diabetes

Forty million individuals worldwide suffer from type 1 diabetes. This disease is managed by insulin therapy in a vast majority of patients because of the limited accessibility of beta cell replacement therapies (pancreas or islet... ver más

31/12/2024

UNIGE

7M€

Presupuesto del proyecto: 7M€

Líder del proyecto

UNIVERSITE DE GENEVE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 8 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-12-31

SC1-BHC-07-2019: Regenerative medicine: from new ins...

I+D

Cerrada hace 5 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

8 Participantes

UNIGE

2.00M€ | Lider

UNIVERSITE LYON 1 CLAUDE BER...

523.81K€ | Participante

UPO

936.88K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

Micro Pancreas Cure Diabetes by Injection of Micro Pancreas Cell Therapy 4M€ Cerrado

Neobetacell Neogenesis of new functional Beta Cells through Modulation o... 1M€ Cerrado

BAPrefinement Bioartificial Pancreas refinement 100K€ Cerrado

DELIVER DELIVERy of advanced therapies for diabetes training network 2M€ Cerrado

TRANSBETA In Vitro Derivation of Beta Cells by Ectopic Expression of P... 100K€ Cerrado

BIOSID A bioartificial pancreas to treat type 1 diabetes optimizat... 7M€ Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2019-12-06
Fecha Fin: 2024-12-31

Líder del proyecto

UNIVERSITE DE GENEVE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 7M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Forty million individuals worldwide suffer from type 1 diabetes. This disease is managed by insulin therapy in a vast majority of patients because of the limited accessibility of beta cell replacement therapies (pancreas or islet of Langerhans transplantation). There is an urgent need for the development of a beta cell replacement therapy that will be available to larger numbers of type 1 diabetic patients. The VANGUARD project aims to deliver an Advanced Therapeutic Medicinal Product (ATMP) of high translational potential, with properties of increased functionality and implantability and protection from immune destruction. We will construct a bioartificial pancreas by assembling insulin- producing organoids, composed of islet cells, human amniotic epithelial cells (hAEC) and blood outgrowth endothelial cells (BOECs), into an amniotic membrane-derived hydrogel. Components of the amniotic membrane will provide extracellular matrix and mechanical protection and confer their well-defined anti-inflammatory and immunomodulatory properties to the constructs. hAECs will be genome-edited to overexpress and locally release immunomodulatory molecules (HLA-G, HLA-E, CD47 and PD-L1) and endothelial cells will enhance graft revascularization. Functionality, biocompatibility, potency and safety of the bioartificial pancreas will be assessed in vitro and in vivo by implantation in mice reconstituted with a human immune system as pre-clinical model. The consortium consists of 5 academic institutions with leading scientists in their field, 2 SMEs and 1 NGO with expertise in ethical and social aspects of transplantation. The ATMP delivered upon completion of the project will provide a model for rapid development of a bioartificial pancreas, utilizing infinite sources of insulin-producing cells (stem cell-derived, xenogeneic), and available to all type 1 diabetic patients before they develop the devastating chronic complications of the disease.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores